Shanghai Aopen Medical Technology

Shanghai Aopen Medical Technology Co., Ltd., founded in 2017, is a company focused on the development, manufacturing, and sales of medical robots. The firm was established by Dr. Liu Daozhi, who also serves as the founder and executive partner of BlueRun Ventures (山蓝资本). Dr. Liu holds a Ph.D. from Nankai University and completed postdoctoral research at the University of Oxford. His prior experience includes serving as Senior Vice President of Emerging Businesses and R&D at MicroPort Scientific Corporation, and as General Manager of MicroPort Orthopedics. This background in medical devices and venture capital has shaped the company's direction.

The company operates in the high-tech medical device market, specifically targeting the field of vascular interventional surgical robotics. Its primary clients are hospitals and vascular surgeons. Aopen Medical's business model centers on the research, development, and eventual sale of its robotic surgical systems to these medical institutions. The company has successfully raised significant capital through multiple funding rounds, including a Series C in April 2025, a Series B in August 2021, and a Series A in September 2020, to finance clinical trials, R&D, and regulatory certifications.

Aopen Medical's flagship product is the ALLVAS® pan-vascular interventional surgical robot. This system is designed to assist surgeons in performing a wide range of procedures, such as coronary, peripheral, neurological, and tumor interventions. A key feature of the ALLVAS® system is its compatibility with a full range of interventional surgical consumables, a platform-based design intended to address limitations of other systems. The robot aims to enhance operational precision and stability while allowing surgeons to operate remotely, thereby reducing their exposure to X-ray radiation. The system also incorporates features for full-process automation and a surgical navigation system. In April 2023, the ALLVAS® robot was used to complete a remote robotic-assisted PCI (Percutaneous Coronary Intervention) surgery, a notable achievement for the company.

Keywords: surgical robotics, medical devices, vascular intervention, endovascular surgery, coronary intervention, neurointervention, peripheral intervention, robotic-assisted surgery, medical technology, remote surgery, medtech, ALLVAS, interventional oncology, radiation reduction, surgical navigation, clinical trials, medical robot manufacturing, healthcare technology, Shanghai, Liu Daozhi, pan-vascular